We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DuPont de Nemours, Inc. (DD - Free Report) recently announced the launch of its Liveo Pharma TPE Ultra-Low Temp Tubing, a new thermoplastic elastomer tubing. This product has been designed keeping in mind the ability required to withstand low temperatures in many biopharmaceutical processing applications.
This ISO Class 7 cleanroom-manufactured tubing is sterilizable, weldable and sealable, and offers improved elastomer toughness and ductility. The product’s resistance to bending, good pumpability, low spallation, along with phthalate-free tubing's purity make it an ideal solution for meeting the biopharmaceutical processing industry's needs.
The new Liveo Pharma TPE Ultra-Low Temp Tubing is the second TPE tubing product introduced by DD in recent years and joins Liveo Pharma TPE Tubing in its solution portfolio for biopharma processing applications. The range of biopharma processing applications includes numerous silicone-based tubing and overmolded assembly products. The new solution is produced with high-quality principles and facilitates compatibility with alternative TPE tubing offerings.
DD stock has lost 2.4% over the past year compared with the 18.8% decline of the industry.
Image Source: Zacks Investment Research
DuPont anticipates full-year 2025 net sales to be in the range of $12,800-$12,900 million. Operating EBITDA for the full year is forecasted to be $3,325-$3,375 million, while adjusted earnings are projected to be $4.30-$4.40 per share.
The Zacks Consensus Estimate for Ingevity’s current-year earnings is pegged at $4.45 per share. NGVT’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with the average surprise being 202.9%.
The Zacks Consensus Estimate for Axalta’s current-year earnings is pegged at $2.51 per share. AXTA’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 16.28%.
The Zacks Consensus Estimate for Carpenter Technology’s current fiscal-year earnings is pegged at $6.95 per share. CRS’ earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 15.7%. Its shares have soared 154.6% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DuPont Introduces Liveo Pharma TPE Ultra-Low Temp Tubing
DuPont de Nemours, Inc. (DD - Free Report) recently announced the launch of its Liveo Pharma TPE Ultra-Low Temp Tubing, a new thermoplastic elastomer tubing. This product has been designed keeping in mind the ability required to withstand low temperatures in many biopharmaceutical processing applications.
This ISO Class 7 cleanroom-manufactured tubing is sterilizable, weldable and sealable, and offers improved elastomer toughness and ductility. The product’s resistance to bending, good pumpability, low spallation, along with phthalate-free tubing's purity make it an ideal solution for meeting the biopharmaceutical processing industry's needs.
The new Liveo Pharma TPE Ultra-Low Temp Tubing is the second TPE tubing product introduced by DD in recent years and joins Liveo Pharma TPE Tubing in its solution portfolio for biopharma processing applications. The range of biopharma processing applications includes numerous silicone-based tubing and overmolded assembly products. The new solution is produced with high-quality principles and facilitates compatibility with alternative TPE tubing offerings.
DD stock has lost 2.4% over the past year compared with the 18.8% decline of the industry.
Image Source: Zacks Investment Research
DuPont anticipates full-year 2025 net sales to be in the range of $12,800-$12,900 million. Operating EBITDA for the full year is forecasted to be $3,325-$3,375 million, while adjusted earnings are projected to be $4.30-$4.40 per share.
DD’s Zacks Rank and Key Picks
DD currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Ingevity Corporation (NGVT - Free Report) , Axalta Coating Systems (AXTA - Free Report) and Carpenter Technology Corporation (CRS - Free Report) . While NGVT and AXTA sport a Zacks Rank #1 (Strong Buy) each at present, CRS carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Ingevity’s current-year earnings is pegged at $4.45 per share. NGVT’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with the average surprise being 202.9%.
The Zacks Consensus Estimate for Axalta’s current-year earnings is pegged at $2.51 per share. AXTA’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 16.28%.
The Zacks Consensus Estimate for Carpenter Technology’s current fiscal-year earnings is pegged at $6.95 per share. CRS’ earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 15.7%. Its shares have soared 154.6% in the past year.